AHAndrew M. Harding

Andrew M. Harding

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew M. Harding has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Implications of differences between point‐of‐care blood gas analyser and laboratory analyser potassium results on hyperkalaemia diagnosis & treatment

    by Jasmin Pradhan, Andrew M. Harding, Simone E. Taylor, Que Lam

    Background: Hyperkalaemia is managed in the emergency department (ED) following measurement of potassium results by blood gas analysers (BGA) or laboratory analysers (LAB).Aims: To determine the prevalence of clinically significant differences between BGA and LAB potassium results and the impact on ED hyperkalaemia management.Methods: Retrospective analysis of time‐matched ED BGA and LAB potassium samples from 2019 to 2020 (taken within 15 min, one or both results ≥6.0 mmol/L). Mean differences and 95% limits of agreement (LoA) were determined for pairs with one or both results ≥6.0 mmol/L and a separate 500 consecutive sample pairs.Results: Four hundred eighty‐eight matched BGA and LAB samples met the inclusion criteria. Of these, 201 (41.2%) differed by ≤0.5 mmol/L, 169 (34.6%) included a haemolysed LAB sample, and 12 (2.5%) had an unreportable BGA sample. One hundred six (21.7%) pairs differed by >0.5 mmol/L, and 60/106 (57%) had normal LAB potassium results, but BGA indicated moderate/severe hyperkalaemia (two of these pairs received hyperkalaemia treatment). Of patients with a haemolysed LAB sample, or where pairs differed by >0.5 mmol, 48 were treated with insulin and five (10.4%) experienced hypoglycaemia. Mean differences and LoA for pairs with LAB results <6.0 mmol/L but BGA ≥6.0 mmol/L demonstrated unacceptable agreement, with 18 (25.7%) BGA results exceeding 8.0 mmol/L.Conclusions: Potentially significant discordance may occur between BGA and LAB potassium results. Clinicians need to be aware of factors impacting both analytical methods' accuracy (such as poor venepuncture or sample handling, (K) EDTA interference) and undetectable haemolysis with BGA measurements. We recommend BGA hyperkalaemia be confirmed with LAB results using a non‐haemolysed sample where time permits.


  • Improving the safety of anticoagulation initiation in patients discharged from the emergency department

    by Andrew M Harding, Elise Mitri, Michael Yeoh

    Objective To improve the safety of anticoagulation initiation by increasing the proportion of patients reviewed by a pharmacist. Methods An electronic intervention was developed to ensure all patients prescribed anticoagulation on discharge were reviewed by an ED pharmacist. Safe anticoagulation initiation was compared for patients seen and not seen. Results The intervention increased the number of patients seen by an ED pharmacist. Pre-intervention (n = 238) 84.5% of patients were reviewed by a pharmacist. Post-intervention (n = 253) 99.6% of patients were reviewed by a pharmacist. Of the 38 patients not reviewed by a pharmacist, 20 (52.6%) had safe anticoagulation initiation and in a sample of 40 patients reviewed by a pharmacist, all 40 (100%) had safe anticoagulation initiation (52.6% vs 100%, P < 0.001). Conclusion The real-time electronic intervention improved the number of patients reviewed by a pharmacist. ED pharmacist reviewed patients were more likely to have safe anticoagulation initiation.


  • Estimating the proportion of patients who transition to long-term opioid use following oxycodone initiation in the emergency department

    by Jennie P Nguyen, Andrew M Harding, Shaun L Greene

    Objective To report the number of patients discharged from ED with oxycodone immediate release (IR) over 12 months and estimate the proportion who potentially transition to long-term opioid use and subsequent injectable heroin use. Methods Retrospective observational data were collected from a major tertiary-referral metropolitan ED in Melbourne, Australia, describing the number of patients discharged with an oxycodone IR prescription and proportion of discharge scripts filled. These data were projected against published data reporting trends on patients' trajectory to long-term opioid use, to subsequently estimate the proportion of patients from this cohort that may transition to injectable heroin use. Results Of the 87 551 ED presentations in 2018, there were 4843 prescriptions written for oxycodone IR for 4102 different patients. An estimated 279 patients may become long-term opioid users following initial ED presentation. Of these 279 patients, 1.4 patients may potentially transition to injectable heroin use. Conclusion Modelling opioid use behaviour in an ED population demonstrated the potential development of unintentional long-term opioid use, and associated harms. Prospective study is required to fully understand trajectories of patients dispensed outpatient therapy from Australian EDs.


  • A prospective, randomized, double‐blind trial of intravenous chlorpromazine versus intravenous prochlorperazine for the treatment of acute migraine in adults presenting to the emergency department

    by Sarah E. Hodgson, Andrew M. Harding, Elyssia M. Bourke, David M. Taylor, Shaun L. Greene

    Objective: To compare the efficacy of intravenous chlorpromazine versus intravenous prochlorperazine for the treatment of acute migraine in adults presenting to the emergency department (ED). Background: Migraine is a common, incapacitating neurological condition. Although chlorpromazine and prochlorperazine are known to be safe, efficacious treatments for migraine, they have never been directly compared. Design: We performed a prospective, randomized, double‐blind clinical trial at a tertiary hospital in Melbourne, Australia. Adults aged 18–65 years, who presented with migraine, were eligible for recruitment. Sixty‐six patients were randomized to either chlorpromazine 12.5 mg or prochlorperazine 12.5 mg, both infused in 500 ml of sodium chloride 0.9% over 30 min. Headache severity score, nausea severity score, and the presence of photophobia and phonophobia were assessed at 0, 30, 60, and 120 min. Adverse effects and the need for rescue therapy were recorded. The primary outcome was a reduction in headache severity score from baseline at 60 min post‐commencement of the study medicine infusion. Results: Sixty‐five patients were included in the analysis. There was a median reduction in headache severity score at 60 min of 3.0 (interquartile range 1.0–4.0) in the chlorpromazine arm versus 2.0 (1.0–4.0) in the prochlorperazine arm (median difference −0.5 (95% confidence interval, −1.9 to 0.9)). We saw no evidence of a difference in secondary outcomes at 30, 60, or 120 min. Side effects were reported in 16/32 (50%) patients in the chlorpromazine group versus 7/33 (21%) in the prochlorperazine group ( p = 0.020). Rescue therapy was required in 7/32 (22%) patients in the chlorpromazine group versus 12/33 (36%) in the prochlorperazine group ( p = 0.277). Conclusions: Both chlorpromazine and prochlorperazine are efficacious treatments for acute migraine in adult patients presenting to the ED. This trial found no evidence of superiority of either agent over the other. Caution should be used when prescribing these medicines in the borderline hypotensive patient; in that circumstance, prochlorperazine should be preferentially used.


  • Comprehensive identification of medication‐related problems occurring prior to, during and after emergency department presentation: An Australian multicentre, prospective, observational study

    by Simone E Taylor, Elise A Mitri, Andrew M Harding, David McD Taylor, Adrian Weeks, Leonie Abbott, Pani Lambros, Dona Lawrence, Dana Strumpman, Reyhan Senturk‐Raif, et al.

    Objective: Patients present to EDs with various medication‐related problems (MRPs). MRPs are also associated with ED care, occurring during ED presentation or shortly afterwards. The aim of the present study is to describe the prevalence and nature of MRPs that occur prior to, during or shortly after leaving ED.Methods: We undertook a prospective, observational study in nine Australian EDs. Blocks of 10 consecutive adult patients who were not seen by a pharmacist in ED and who presented at pre‐specified times were identified. Within 1 week of ED discharge, a pharmacist interviewed patients and undertook a medical record review to determine their medication history, patients' understanding of treatment, potential MRP risk factors and manage any identified MRPs.Results: A total of 904 patients were recruited: 14.8% aged ≥80 years, 18.9% taking more than eight regular medications; 581 MRPs were identified; 287 (49.4%, 95% confidence interval [CI] 45.3–53.5%) of moderate‐high significance. Most highly significant MRPs involved high‐risk medications, particularly strong opioids, insulin and anti‐coagulants. The most common types of MRPs were prescribing errors (46.8%), patient adherence/knowledge issues (31.2%) and adverse drug reactions (7.4%). Of all patients, 381 (42.1%, 95% CI 38.9–45.5%) had at least one MRP; 31.4% (95% CI 28.4–34.6%) had MRPs that could be identified or managed by screening at ED presentation and 12.4% (95% CI 10.4–14.8%) had MRPs that could be identified or managed by screening at ED discharge.Conclusions: Patients experienced a range of MRPs throughout the ED continuum of care. From these data, screening tools will be developed so that ED clinicians may identify patients at greatest risk of MRPs.


  • Standard of practice in emergency medicine for pharmacy services

    by Susan Welch, Elizabeth Currey, Elizabeth Doran, Andrew Harding, Cristina Roman, Simone Taylor, Alicia Thomas, Courtney Munro


  • Misappropriation of medications and equipment in the emergency department

    by Andreas Hendarto, Andrew M. Harding, Joyce A. Kant, Michelle T. Hunter, David McD Taylor


  • Modifying emergency department electronic prescribing for outpatient opioid analgesia

    by Grace D Schwartz, Andrew M Harding, Síne R Donaldson, Shaun L Greene

    Objectives: The aim of this study was to examine how changing the electronic ordering sequences for opioid analgesics affected ED outpatient prescribing, and subsequent unused opioid tablets remaining in the community available for diversion.Methods: A descriptive before and after study in adult patients prescribed an opioid analgesic by an ED prescriber for use in the outpatient setting. The hospital electronic prescribing system (FirstNet™) was modified to include smaller quantities of opioid analgesics for discharge. The change in quantity of opioid prescribed and change in quantity of opioid analgesic remaining in the community at follow up was measured pre‐ and post‐intervention using a structured telephone interview.Results: Pre‐ and post‐intervention, 102 and 106 patients were interviewed, respectively. Percentage of prescriptions for oxycodone quantity five tablets increased from 3% to 32% and for quantity 20 tablets fell from 40% to 24% post‐intervention. For paracetamol with codeine, prescriptions for quantity 10 tablets increased from 2% to 24% while for quantity 20 tablets fell from 98% to 76%. Mean number of tablets prescribed per patient fell from 13.8 (SD = 5.1) to 10.8 (SD = 5.6) for oxycodone and from 19.8 (SD = 1.5) to 17.6 (SD = 4.2) for paracetamol with codeine. Fifty‐eight percent of patients in both pre‐ and post‐intervention groups used half or less of the medication prescribed.Conclusion: Modification of an ED electronic prescribing system reduced overall quantities of opioid analgesics supplied and subsequently stored in the community but did not change the proportion of patients (>50%) who reported using half or less of their prescribed opioid medication.


  • Evaluation of medication dose omissions amongst inpatients in a hospital using an electronic Medication Management System

    by Katherine V. Hunt, Andrew M. Harding, Simone E. Taylor, Colin Curtain

    Rationale, aims, and objectives: Whilst many dose omissions cause no patient harm, inappropriate dose omissions have been associated with increased length of hospital stay, risk of sepsis, and mortality. This study aimed to comprehensively describe the prevalence and nature of omitted doses overall and of high risk medication dose omissions in an organization using an electronic Medication Management System.Methods: A retrospective cross‐sectional study was undertaken in an Australian tertiary referral health service. All routinely documented electronic inpatient dose administration records from 1st July 2014 to 30th June 2015 were included. Period prevalence and characteristics of dose omissions overall and of high‐risk medication dose omissions were determined.Results: During the study period, 3.3 million inpatient doses were scheduled for administration, with doses endorsed as “not given” comprising 6.2% of all scheduled doses. Non‐valid dose omissions (medication not available or no justification documented) comprised 1.2% of scheduled doses. Patient refusal accounted for one third of all dose omissions, while for 12% no explanation was provided and 7% were endorsed “medication not available”. High‐risk medications accounted for 20% of all dose omissions. One in 20 antimicrobial doses scheduled were omitted, and of these, 17% were due to patient refusal.Conclusion: The period prevalence of dose omissions in this large study after electronic Medication Management System implementation is similar to that found when paper charts were used. Although most dose omissions appear appropriate, many orders were not given due to patient refusal or with no documented justification. Interventions to minimize unintentional dose omissions are indicated.